Small Caps Can Only Lead Stocks So High: Stock Market Today
The main U.S. equity indexes were down for the week, but small-cap stocks look as healthy as they ever have.
Stocks struggled for most of Friday's session and closed lower. They were down on a weekly basis, but the long-term trend remains up for all three main U.S. equity indexes as participation continues to broaden beyond the Magnificent 7. And incoming economic data remains solid.
By the closing bell, the broad-based S&P 500 was off 0.06% at 6,940, the tech-heavy Nasdaq Composite had slipped 0.06% to 23,515, and the blue-chip Dow Jones Industrial Average was down 0.2% at 49,349.
The Russell 2000 Index was up again, though, and it's a good sign for the bull market that small-cap stocks are doing well.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"All the major indexes are in the green year to date," Louis Navellier of Navellier & Associates writes, "with the Russell 2000 leading by far." Indeed, the Russell 2000 is trading at new all-time highs. "It's encouraging that small caps are so strong; it reflects a risk-on sentiment about the economy."
The Federal Reserve said today that industrial production was up a better-than-expected 0.4% in December and that November's print was revised upward to 0.4%. "Overall output broke through the tape with a combined two-month gain that is about as strong as we saw all year," Wells Fargo economists Shannon Grein and Tim Quinlan observe.
Note that the stock and bond markets are closed on Monday in observance of Martin Luther King Day.
What does IBRX do?
ImmunityBio (IBRX,+39.8%) began the week with a market cap of $2.29 billion and will end it well north of $5 billion after rising more than 125% since last Friday.
Management of the biotech stock said it expects to see revenue growth of 700% for its bladder cancer drug, Anktiva. ImmunityBio also announced the approval of Anktiva by the Saudi Food and Drug Authority for the treatment of non-small cell lung cancer.
"Risk-on" names such as ImmunityBio make for a good "field bet" through one of the best biotech ETFs to buy.
Price action for the SPDR S&P Biotech ETF (XBI, -0.1%) vs the iShares Biotechnology ETF (IBB, -0.4%) today reflects the former's heavier weighting to mid- and small-cap stocks such as IBRX.
More and more Trump stocks
GE Vernova (GEV, +6.1%) was up as much as 7.8% on reports that President Donald Trump and governors of states in the northeast will ask the biggest electricity grid operator in the U.S. to hold an emergency auction so hyperscalers driving the AI boom will bid on and pay for the construction of new power plants to support their data centers.
PJM Interconnection serves about 65 million customers in 13 states and Washington, D.C. The president teased the plan in a post on Truth Social on Monday. "I never want Americans to pay higher Electricity bills because of Data Centers," the president said.
Trump said his team has been working with Microsoft (MSFT), which he said "will make major changes beginning this week to ensure that Americans don't 'pick up the tab' for their POWER consumption, in the form of paying higher Utility bills."
GE Vernova was spun off from General Electric in April 2024. The old GE survives as GE Aerospace (GE) and is one of five stocks to buy for a Trump presidency.
Susquehanna analysts Charles Minervino and Eric Clay are "bullish on GEV given its position as the leading gas turbine supplier globally in an environment where load growth expectations continue to accelerate."
Looking for more timely stock market news to help gauge the health of your portfolio? Sign up for Closing Bell, our free newsletter that's delivered straight to your inbox at the close of each trading day.
Its electrification segment is also "well positioned to take advantage of secular trends around grid upgrades." The analysts rate GEV Positive (Buy) with a 12-month target price of $775.
Constellation Energy (CEG) and Vistra (VST), which rallied 58.8% and 17.7%, respectively, in 2025 based on rising demand for electricity from its existing power plants to fuel data centers and the AI boom, were down 9.8% and 7.5% on Friday.
Related content
- How the Stock Market Performed in the First Year of Trump's Second Term
- Is the Stock Market Open on Martin Luther King Day?
- Earnings Calendar and Analysis for This Week (January 19-23)
-
Ask the Editor: Tips for Filing Your 1040Ask the Editor In this week's Ask the Editor Q&A, Joy Taylor answers questions on preparing and filing your 2025 Form 1040.
-
Is Direct Primary Care Right for Your Health Needs?With the direct primary care model, you pay a membership fee for more personalized medical services.
-
Smart Ways to Share a Credit CardAdding an authorized user has its benefits, but make sure you set the ground rules.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You're in the 2% Club and Have a Pension, the 60/40 Portfolio Could Hold You BackIncome from your pension, savings and Social Security could provide the protection bonds usually offer, freeing you up for a more growth-oriented allocation.
-
Bye-Bye, Snowbirds: Wealthy Americans Are Relocating Permanently for Retirement — and This Financial Adviser Can't Fault Their LogicWhy head south for the winter and pay for two properties when you can have a better lifestyle year-round in a less expensive state?
-
Consider These 4 Tweaks to Your 2026 Financial Plan, Courtesy of a Financial PlannerThere's never a bad time to make or review a financial plan. But recent changes to the financial landscape might make it especially important to do so now.
-
We Know You Hate Your Insurance, But Here's Why You Should Show It Some LoveSure, it's pricey, the policies are confusing, and the claims process is slow, but insurance is essentially the friend who shows up during life's worst moments.
-
Dow Adds 292 Points as Goldman, Nvidia Soar: Stock Market TodayTaiwan Semiconductor's strong earnings sparked a rally in tech stocks on Thursday, while Goldman Sachs' earnings boosted financials.
-
What's in Store for the Stock Market in 2026?Wall Street expects the bull market to keep running in the year ahead.
-
Is a Caregiving Strategy — for Yourself and Others — Missing From Your Retirement Plan?Millions of people over 65 care for grandkids, adult kids or aging parents and will also need care themselves. Building a caregiving strategy is crucial.
